Search

HealthDay News — Accelerated intermittent theta-burst stimulation (aiTBS) is significantly more effective than sham stimulation for depressive symptom reduction in patients with treatment-resistant bipolar depression, according to a study published [...]

The Food and Drug Administration (FDA) has expanded the approval of Fanapt[sup.®] (iloperidone) to include the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. [...]

People with Alzheimer’s disease and related dementias who receive home health are likely getting prescribed https://www.mcknights.com/news/clinical-news/dementia-diagnosis-offers-missed-opportunity-to-cut-meds-study-finds/ too often, according to a new study. The research was published Wednesday in the [...]

The Food and Drug Administration (FDA) has approved Abilify Asimtufii[sup.®] (aripiprazole extended-release injectable suspension) for the treatment of schizophrenia in adults and as maintenance monotherapy treatment of bipolar I disorder [...]

The Food and Drug Administration (FDA) has approved Rykindo[sup.®] (risperidone extended-release injectable suspension for intramuscular [IM] use) for the treatment of schizophrenia in adults, and as monotherapy or as adjunctive [...]

The Food and Drug Administration (FDA) has approved Rykindo[sup.®] (risperidone extended-release injectable suspension for intramuscular [IM] use) for the treatment of schizophrenia in adults, and as monotherapy or as adjunctive [...]

Iloperidone was associated with significant improvement in adults with bipolar I disorder, according to results from a phase 3 study. Iloperidone, an atypical antipsychotic, is currently marketed under the brand [...]

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable for the treatment of schizophrenia in adults and for maintenance monotherapy [...]

The Food and Drug Administration (FDA) has approved Igalmi[sup.™] (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Igalmi [...]

The Food and Drug Administration (FDA) has approved Caplyta (lumateperone) for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive [...]

Lybalvi® (olanzapine and samidorphan) is now available for the treatment of schizophrenia in adults and for bipolar I disorder in adults for acute treatment of manic or mixed episodes as [...]

Bipolar disorder is a mood disorder that affects 2% of the population worldwide and is associated with high rates of relapse and suicide. (1) Statistics on relapse rates show the [...]

Alkermes; Pharmacologic class: Atypical antipsychotic + opioid antagonist; Active ingredients: Olanzapine, samidorphan; 5mg/10mg, 10mg/10mg, 15mg/10mg, 20mg/10mg; tabs; Indication: Acute treatment of manic or mixed episodes in bipolar I disorder as [...]

The FDA has expanded the indication of Latuda (lurasidone HCI; Sunovion) to include the treatment of pediatric patients aged 10-17 years with major depressive episodes associated with bipolar I disorder. [...]

Otsuka and Lundbeck announced that the FDA has approved Abilify Maintena (aripiprazole) extended-release injectable suspension for the maintenance monotherapy treatment of bipolar I disorder (BP-I) in adults. Abilify Maintena is [...]

Company: Actavis Rx Pharmacologic class: Atypical antipsychotic Active ingredients: Cariprazine 1.5mg, 3mg, 4.5mg, 6mg; capsules. Indication: Treatment of schizophrenia. Acute treatment of manic or mixed episodes associated with bipolar I [...]

Allergan has announced the availability of Vraylar (cariprazine) capsules for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in [...]

Amneal has launched Aripiprazole Oral Solution, the generic version of Otsuka's Abilify Oral Solution. Aripiprazole is an atypical antipsychotic indicated for the treatment of schizophrenia, manic and mixed episodes associated [...]

Aurobindo Pharma has received the approval from the FDA for Olanzapine Orally Disintegrating Tablets, the generic version of Eli Lilly's Zyprexa Zydis. Zyprexa Zydis is indicated to treat Bipolar I [...]

The FDA has approved Aripiprazole, the first generic version of Otsuka's Abilify. Abilify is an atypical antipsychotic indicated for multiple psychiatric disorders, including acute and maintenance treatment of manic or [...]

Actavis announced that the FDA has approved its sNDA for Saphris (asenapine) as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric [...]

The FDA has approved Impax's Lamotrigine Orally Disintegrating Tablets, the generic version of GlaxoSmithKline's Lamictal ODT. Lamictal ODT is indicated for the maintenance treatment of bipolar disorder and as adjunct [...]

Breckenridge announced that the FDA has approved Quetiapine Fumarate Tablets, the generic version of AstraZeneca's Seroquel. Seroquel is an atypical antipsychotic indicated for the treatment of schizophrenia; acute mania in [...]

Mylan announced the launch of Olanzapine Orally Disintegrating Tablets (ODT), the generic version of Eli Lilly's Zyprexa Zydis. Zyprexa Zydis is a thienobenzodiazepine indicated for the treatment of schizophrenia or [...]

Company: Alexza Pharmaceuticals R Pharmacologic class: Dibenzoxazepine Active ingredients: Loxapine 10mg; powder for oral inhalation. Indication: Acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Limitations [...]

The FDA has approved two new indications for Latuda (lurasidone HCl; Sunovion) to treat adults with major depressive episodes associated with bipolar I disorder (bipolar depression) both as monotherapy and [...]

Wockhardt has received final approval from the FDA for Felodipine Extended-Release Tablets, the generic version of AstraZeneca's Plendil, a calcium channel blocker indicated for the treatment of hypertension as monotherapy [...]

Cariprazine (Forest) an orally active dopamine [D.sub.3]-preferring [D.sub.3]/[D.sub.2] receptor partial agonist being studied for the treatment of acute mania associated with bipolar 1 disorder--Phase [...]

Abilify (aripiprazole; Bristol-Myers Squibb and Otsuka) has been approved as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder. See Section [...]

The FDA has approved Abilify (aripiprazole, from Bristol-Myers Squibb and Otsuka) for irritability associated with autistic disorder in pediatric patients 6-17 years of age, including symptoms of aggression towards others, [...]

Seroquel XR (quetiapine fumarate extended-release tablets, from AstraZeneca) has been approved by the FDA as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD). Seroquel XR is already [...]

Zyprexa Relprevv (extended-release olanzapine injectable suspension, from Lilly) has been approved to treat schizophrenia in adults. Additionally, Zyprexa tablets were also approved to treat schizophrenia and manic or mixed episodes [...]

Geodon (ziprasidone HCl, from Pfizer) capsules have been approved by the FDA for the adjunctive maintenance treatment of bipolar I disorder in adults. It is used in combination with lithium [...]

Company: Schering, a division Rx of Merck & Co. Pharmacologic class: A typical antipsychotic (dibenzo-oxepino pyrrole). Active ingredient: Asenapine 5mg, 10mg; sublingual (SL) tabs. Indications: For the acute treatment of: [...]

Saphris (Approved Aug 14) Acute treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Zenpep (Approved Aug 28) Delayed-release capsules for [...]

Abilify (aripiprazole, from Bristol-Myers Squibb and Otsuka) has been approved for the maintenance treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features, in [...]

Abilify (aripiprazole, from Otsuka and Bristol-Myers Squibb) has been approved for the acute treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features in [...]

Highlights of recent developments Cardiovascular Nebivolol (Bystolic, from Forest) a novel β-blocker under review for the treatment of hypertension--Approved PRT060128 (from Portola) an antiplatelet agent that inhibits the ADP receptor [...]

Cardiovascular Niacin extended-release + simvastatin (Simcor, from Abbott) an investigational fixed-dose combination of niacin extended-release and simvastatin for the treatment of dyslipidemia--NDA submitted Prasugrel (from Daiichi-Sankyo and Lilly) an oral [...]

Abilify (aripiprazole, from Otsuka and Bristol-Myers Squibb) has been approved for the treatment of schizophrenia in adolescents 13-17yrs old. Abilify is already indicated for use in adults with schizophrenia and [...]